Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 8/20 | 0.60 |
| ▸ | BCHE | P06276 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.58 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.57 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.57 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.57 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6092095 | 0.98 | CCR3 (0.65) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL5969011 | 0.90 | CCR3 (0.58) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL537415 | 0.90 | CCR3 (0.58) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL4621517 | 0.90 | CCR3 (0.58) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL8825330 | 0.90 | CCR3 (0.63) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL7272428 | 0.89 | CCR3 (0.61) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL15140944 | 0.87 | CCR3 (0.73) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL3107807 | 0.86 | CCR3 (0.71) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL1061878 | 0.86 | CCR3 (0.71) | CCR3ACHEBCHEALDH1A1CXCR4 | |
| SCHEMBL15933900 | 0.85 | MAPT (0.68) | ACHEALDH1A1CXCR4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737875-B2 | Affinity reagents for protein purification | IMPOSSIBLE FOODS INC. (US) | 2017-08-22 | — | — | US | claimed |
| CN-104620104-B | Affinity Reagents for Protein Purification | 非凡食品有限公司 | 2017-03-01 | — | — | CN | claimed |
| US-7462613-B2 | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | claimed |
| US-20060122229-A1 | 4,5-diarylthiazole derivatives as cb-1 ligands | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | claimed |
| CN-1753672-A | 4,5-diarylthiazole derivatives as cb-1 ligands | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | claimed |
| EP-1581214-A1 | 4,5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS | Astrazeneca AB (SE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004058255-A1 | 4, 5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | claimed |
| EP-0385044-A1 | New piperidine derivatives as antihistaminics | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1990-09-05 | — | — | EP | claimed |
| CN-116283769-B | Cyclobutane combination pyridine sulfonamide compound | 绍兴市上虞区武汉理工大学高等研究院 | 2025-03-25 | — | — | CN | disclosed |
| WO-2025022031-A1 | NEW DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024026026-A1 | HIGH THROUGHPUT IN VIVO SCREENING OF LIPID NANOPARTICLES | TRUSTEES OF TUFTS COLLEGE (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | SENDA BIOSCIENCES INC (US) | 2023-07-27 | — | — | US | disclosed |
| CN-116283769-A | Cyclobutane-pyridine sulfonamide compound | 绍兴市上虞区武汉理工大学高等研究院 | 2023-06-23 | — | — | CN | disclosed |
| US-4849431-A | ANTICHOLINESTERASE ACTIVITY | EISAI CO., LTD. (JP) | 1989-07-18 | — | — | US | disclosed |
| CN-1030752-A | Preparation method of cyclic amine compound | EISAI CO LTD (JP) | 1989-02-01 | — | — | CN | disclosed |
| EP-0296560-A2 | 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease | Eisai Co., Ltd. (JP) | 1988-12-28 | — | — | EP | disclosed |
| US-4709010-A | TREATING OR PREVENTING HYPERTENSION OR HYPERALDESTERONISM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-11-24 | — | — | US | disclosed |
| EP-0229391-A1 | Piperidine derivate, its use and pharmaceutical composition containing it | Eisai Co., Ltd. (JP) | 1987-07-22 | — | — | EP | disclosed |
| EP-0179352-A2 | Peptides | MERCK PATENT GmbH (DE) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122229-A1 | 4,5-diarylthiazole derivatives as cb-1 ligands | CNR1, CNR2, NPY4R | CCR3 688/4885ACHE 2463/4885BCHE 940/4885 |
| US-20230234917-A1 | ASPARAGINE DERIVATIVES AND METHODS OF USING SAME | ASNS, SI, NARS1 | CCR3 4321/4885ACHE 1493/4885BCHE 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.